Aquestive Therapeutics Inc (AQST)
2.90
-0.01
(-0.34%)
USD |
NASDAQ |
May 31, 16:00
2.895
0.00 (0.00%)
After-Hours: 20:00
Aquestive Therapeutics Cash from Financing (Quarterly): 81.74M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 81.74M |
| December 31, 2023 | 3.913M |
| September 30, 2023 | 4.979M |
| June 30, 2023 | 4.287M |
| March 31, 2023 | -9.205M |
| December 31, 2022 | 0.234M |
| September 30, 2022 | -0.138M |
| June 30, 2022 | 10.20M |
| March 31, 2022 | 1.298M |
| December 31, 2021 | 5.454M |
| September 30, 2021 | 6.078M |
| June 30, 2021 | 8.686M |
| March 31, 2021 | 9.891M |
| December 31, 2020 | 28.49M |
| September 30, 2020 | -0.007M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.01M |
| March 31, 2020 | -0.037M |
| December 31, 2019 | 39.07M |
| September 30, 2019 | 13.63M |
| June 30, 2019 | -0.493M |
| March 31, 2019 | -2.609M |
| December 31, 2018 | -0.081M |
| September 30, 2018 | 65.27M |
| June 30, 2018 | -5.734M |
| March 31, 2018 | -1.417M |
| December 31, 2017 | -0.567M |
| September 30, 2017 | -0.04M |
| June 30, 2017 | -0.003M |
| March 31, 2017 | 5.024M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-9.205M
Minimum
Mar 2023
81.74M
Maximum
Mar 2024
10.40M
Average
4.633M
Median
Cash from Financing (Quarterly) Benchmarks
| Lifecore Biomedical Inc | 40.93M |
| Harrow Inc | -0.809M |
| Akebia Therapeutics Inc | 18.48M |
| 89bio Inc | 21.03M |
| Humacyte Inc | 62.80M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.38M |
| Cash from Investing (Quarterly) | -0.029M |
| Free Cash Flow | -26.60M |
| Free Cash Flow Per Share (Quarterly) | -0.1415 |
| Free Cash Flow to Equity (Quarterly) | -11.66M |
| Free Cash Flow to Firm (Quarterly) | -6.542M |
| Free Cash Flow Yield | -13.96% |